Janus Henderson Group PLC Has $392.27 Million Stake in Biogen Inc. (BIIB)
Janus Henderson Group PLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 4,585.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,445,560 shares of the biotechnology company’s stock after buying an additional 1,414,707 shares during the quarter. Janus Henderson Group PLC owned 0.68% of Biogen worth $392,265,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Botty Investors LLC grew its holdings in shares of Biogen by 75.0% during the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock valued at $3,048,000 after buying an additional 4,812 shares during the last quarter. Savant Capital LLC grew its holdings in shares of Biogen by 3.7% during the first quarter. Savant Capital LLC now owns 846 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 30 shares during the last quarter. BB&T Securities LLC grew its holdings in shares of Biogen by 25.0% during the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock valued at $3,524,000 after buying an additional 2,598 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Biogen by 2.4% during the first quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock valued at $3,924,258,000 after buying an additional 342,568 shares during the last quarter. Finally, Israel Discount Bank of New York acquired a new position in shares of Biogen during the first quarter valued at about $894,000. Hedge funds and other institutional investors own 87.65% of the company’s stock.
A number of research analysts have recently issued reports on BIIB shares. Vetr upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 price objective for the company in a report on Tuesday, June 27th. Deutsche Bank AG started coverage on shares of Biogen in a report on Friday, June 23rd. They set a “buy” rating and a $315.00 price objective for the company. Robert W. Baird restated a “hold” rating and set a $290.00 price target on shares of Biogen in a report on Friday, August 25th. Credit Suisse Group AG set a $300.00 price target on shares of Biogen and gave the stock a “hold” rating in a report on Friday, July 14th. Finally, BMO Capital Markets boosted their price target on shares of Biogen from $328.00 to $377.00 and gave the stock a “market perform” rating in a report on Wednesday, September 13th. Thirteen equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $330.66.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/janus-henderson-group-plc-has-392-27-million-stake-in-biogen-inc-biib/1612930.html.
Biogen Inc. (BIIB) traded down 0.3533% during mid-day trading on Friday, reaching $325.5855. 214,258 shares of the company were exchanged. The stock has a market capitalization of $68.84 billion, a price-to-earnings ratio of 21.3653 and a beta of 0.77. The stock has a 50 day moving average of $310.27 and a 200-day moving average of $280.91. Biogen Inc. has a one year low of $244.28 and a one year high of $330.98.
Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, topping analysts’ consensus estimates of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $2.81 billion. During the same quarter last year, the business earned $5.21 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. On average, equities analysts expect that Biogen Inc. will post $21.51 earnings per share for the current fiscal year.
In other Biogen news, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the sale, the executive vice president now owns 27,232 shares in the company, valued at approximately $7,761,120. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the sale, the executive vice president now owns 22,258 shares in the company, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by company insiders.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.